Breakthrough Technology Reduces Circulating Tumor Cells in Pancreatic Cancer Patients
In a groundbreaking study published in The British Journal of Cancer, ExThera Medical's Seraph 100 technology, in combination with its Oncobind device, has shown a substantial reduction in circulating tumor cells (CTCs) in patients with pancreatic cancer. Specifically, the Seraph 100 media achieved an impressive 94% average decrease in CTCs when used in vitro on blood samples from individuals with pancreatic ductal adenocarcinoma (PDAC). This development signifies the potential of the device as a powerful standalone therapeutic tool or as a complement to existing treatments like chemotherapy and radiotherapy.
The CE-marked Seraph 100 device operates by simulating human receptors to which CTCs and pathogens bind. As blood passes through the device, CTCs are captured and absorbed onto beads expressing these receptors. This approach not only targets cancer cells but has also previously received emergency use authorization from the FDA for treating Covid-19.
Erin Borger, CEO of ExThera, emphasized the device's ability to significantly enhance and prolong the lives of cancer patients, highlighting the remarkable 94% reduction in CTCs observed in the study. The company is eager to further its research to explore the full impact on patient care. Moreover, the technology fits into the broader landscape of advancements in liquid biopsy, exemplified by Angle's CellKeep slide, which recently secured a European patent for enhancing CTC capture.
Key Takeaways
- ExThera’s Seraph 100 media achieved a 94% reduction in circulating tumor cells from pancreatic cancer patients.
- The Seraph 100 device mimics human receptors to capture and remove cancer cells from blood.
- This technology could be used alone or with chemotherapy and radiotherapy for cancer treatment.
- Seraph 100 previously received FDA authorization for emergency use in treating Covid-19.
- The device's potential to improve cancer patient outcomes is significant, according to ExThera’s CEO.
Analysis
ExThera Medical's Seraph 100 technology, pivotal in reducing pancreatic cancer CTCs, affects the healthcare, biotech, and pharma sectors. It directly challenges existing cancer treatments, potentially reshaping market dynamics. Indirectly, it influences research in complementary technologies, like Angle's CellKeep slide. In the short term, heightened investment and partnerships can be anticipated; in the long term, broader adoption and improved patient outcomes are expected. This breakthrough not only extends lives but also positions ExThera as a leader in innovative cancer therapies.
Did You Know?
- Circulating Tumor Cells (CTCs): These are cancer cells that detach from a primary tumor and circulate in the bloodstream. Their presence can lead to the formation of new tumors (metastasis), a major cause of death in cancer patients. Detecting and reducing CTCs is crucial for managing cancer progression.
- Seraph 100 Technology: This medical device developed by ExThera Medical uses a proprietary media to capture and remove circulating tumor cells and pathogens from the blood. It mimics human receptors, enabling it to specifically target and bind to these harmful elements, thereby purifying the blood.
- Liquid Biopsy: This non-invasive method detects and analyzes cancer-related biomarkers in blood samples, including CTCs, circulating tumor DNA, and other molecules. Liquid biopsies offer a less invasive alternative to traditional tissue biopsies and provide real-time information about tumor progression and treatment response.